FDA Puts Exelixis Cancer Drug on Hold
The FDA needs more time to review a new cancer drug from Exelixis for colon cancer, delaying its potential approval.
Patients and doctors await news on a new colon cancer treatment. The U.S. Food and Drug Administration (FDA) has delayed its decision. This drug comes from Exelixis. It aims to help people with advanced colon cancer.
Exelixis hoped for quick approval for its oral medicine. This medicine works with Roche's drug, Tecentriq. Together, they fight metastatic colorectal cancer. This is a type of cancer that has spread.
The FDA needs more time to look at the drug's information. This means the approval process will take longer than expected. It is common for the FDA to take extra time for complex new treatments. This delay ensures the drug is safe and works well.
This decision affects Exelixis and patients waiting for new options. The company will continue to work with the FDA. Everyone hopes for a positive outcome soon.
Source: FierceBiotech
More from Biotech
